Clozapine rems?

Yes. Clozapine has a REMS (Risk Evaluation and Mitigation Strategy) in the U.S. to help prevent agranulocytosis (a dangerous drop in white blood cells).

Key points:
- What it is for: to ensure safe use of clozapine by monitoring blood counts.
- Who must be enrolled: the patient, the prescribing clinician, and the dispensing pharmacy all participate in the Clozapine REMS.
- How it works: you must have regular lab monitoring (ANC – absolute neutrophil count) and the results must be reported in the REMS database before clozapine can be prescribed or dispensed.
- Typical monitoring schedule (illustrative; exact plan depends on the REMS and labeling):
- Baseline ANC before starting
- Weekly ANC for the first 6 weeks
- Every 2 weeks from weeks 7–52 (months 2–12)
- Every 4 weeks after month 12, if ANC remains stable
- Thresholds and actions: stopping or dose adjustments are guided by ANC values and are defined in the REMS program and the clozapine labeling. In general, a sufficient ANC is required to start and continue therapy; if ANC falls below the REMS-defined threshold, clozapine must be held or discontinued per protocol.
- Other safety notes: the REMS program is in addition to regular medical follow-up and monitoring for other risks (e.g., myocarditis, seizures, metabolic effects) that come with clozapine.

If you want, I can:
- Point you to the official Clozapine REMS site and FDA labeling for exact thresholds.
- Walk through how to enroll (patient, clinician, and pharmacy roles).
- Break down what to expect at a typical clinic visit for REMS monitoring.

Tell me your role (patient, caregiver, or clinician) and what level of detail you’d like.